{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1908.7","value":"47.0"},{"groupId":"OG001","spread":"460.1","value":"1660"},{"groupId":"OG002","spread":"599.9","value":"5810"},{"groupId":"OG003","spread":"196.6","value":"21300"},{"groupId":"OG004","spread":"58.0","value":"46000"},{"groupId":"OG005","spread":"223.5","value":"5690"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"22"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"6"}],"units":"Participants"}],"title":"Cycle 1 Week 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4373.4","value":"228"},{"groupId":"OG001","spread":"142.3","value":"12900"},{"groupId":"OG002","spread":"86.3","value":"42700"},{"groupId":"OG003","spread":"66.2","value":"143000"},{"groupId":"OG004","spread":"76.3","value":"174000"},{"groupId":"OG005","spread":"69.8","value":"25800"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"16"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"6"}],"units":"Participants"}],"title":"Cycle 2 Week 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"22"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"6"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Mezagitamab 45 mg, SC, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in a 28-day treatment cycle until PD, unacceptable toxicities or withdrawal due to other reasons.","id":"OG000","title":"Phase 1 Dose Escalation Cohort: Mezagitamab 45 mg"},{"description":"Mezagitamab 135 mg, SC, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in a 28-day treatment cycle until PD, unacceptable toxicities or withdrawal due to other reasons.","id":"OG001","title":"Phase 1 Dose Escalation Cohort: Mezagitamab 135 mg"},{"description":"Mezagitamab 300 mg, SC, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in a 28-day treatment cycle until PD, unacceptable toxicities or withdrawal due to other reasons.","id":"OG002","title":"Phase 1 Dose Escalation Cohort: Mezagitamab 300 mg"},{"description":"Mezagitamab 600 mg, SC, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in a 28-day treatment cycle until PD, unacceptable toxicities or withdrawal due to other reasons.","id":"OG003","title":"Phase 1 Dose Escalation Cohort: Mezagitamab 600 mg"},{"description":"Mezagitamab 1200 mg, SC, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in a 28-day treatment cycle until PD, unacceptable toxicities or withdrawal due to other reasons.","id":"OG004","title":"Phase 1 Dose Escalation Cohort: Mezagitamab 1200 mg"},{"description":"Mezagitamab 300 mg, SC, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter along with pomalidomide, at product-labelled dose, orally, once daily on Days 1 to 21 and dexamethasone, at product-labelled dose, orally, once on Days 1, 8, 15, and 22 in a 28-day treatment cycle until PD.","id":"OG005","title":"Phase 1 Combination Cohort: Mezagitamab 300 mg + PomDex"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic (PK) analysis set included those participants from the safety analysis set who had sufficient dosing data and mezagitamab concentration-time data to permit the calculation of PK parameters. Number analyzed is the number of participants with data available for analysis at the given timepoint.","reportingStatus":"POSTED","timeFrame":"Cycles 1 and 2: Day 1 pre-dose and at multiple time points (up to 168 hours) post-dose (cycle length=28 days)","title":"Cmax: Maximum Observed Serum Concentration for TAK-079","type":"SECONDARY","unitOfMeasure":"nanograms per milliliter (ng/mL)"}